YC‐1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway
Open Access
- 1 October 2008
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 155 (4) , 505-513
Abstract
Background and purpose: The aim of this study was to elucidate the mechanism of YC‐1{3‐(5′‐hydroxy methyl‐2′‐furyl)‐1‐benzylindazole}‐induced human renal carcinoma cells apoptosis and to evaluate the potency of YC‐1 in models of tumour growth in mice.Experimental approach: YC‐1‐mediated apoptosis was assessed by analysis of MTT, SRB, DAPI staining and flow cytometry analysis. Knockdown of JNK protein was achieved by transient transfection using siRNA. The mechanisms of action of YC‐1 on different signalling pathways involved were studied using western blot. Fas clustering was analysed by confocal microscopy and in vivo efficacy was examined in a A498 xenograft model.Key results: YC‐1 displayed cytotoxicity in renal carcinoma cells at 10−7–10−8 M. Increased condensation of chromatin was observed and an increase in the cell population in subG1 phase. Moreover, YC‐1 triggered mitochondria‐mediated and caspase‐dependent pathways. YC‐1 significantly induced Fas ligand expression, but did not modify either the protein levels of death receptors or ligands. In addition, Fas clustering in cells responsive to YC‐1 was observed, suggesting involvement of a Fas‐mediated pathway. Furthermore, YC‐1 markedly induced phosphorylation of JNK and a JNK inhibitor, SP600125, and siRNA JNK1/2 significantly reversed YC‐1‐induced cytotoxicity and protein expression. We suggest that YC‐1 induced JNK phosphorylation, the upregulation of FasL and Fas receptor clustering to promote the activation of caspases 8 and 3, resulting in apoptosis. Finally, we demonstrated the antitumour effect of YC‐1 in vivo.Conclusions and implications: These data suggest that YC‐1 is a good candidate for development as an anticancer drug.British Journal of Pharmacology (2008) 155, 505–513; doi:10.1038/bjp.2008.292; published online 21 July 2008Keywords
This publication has 32 references indexed in Scilit:
- YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-κB signaling to HIF-1α accumulation during hypoxiaOncogene, 2007
- c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cellsBlood, 2005
- YC-1 [3-(5′-Hydroxymethyl-2′-furyl)-1-benzyl Indazole] Inhibits Endothelial Cell Functions Induced by Angiogenic Factors in Vitro and Angiogenesis in Vivo ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Intracellular Triggering of Fas Aggregation and Recruitment of Apoptotic Molecules into Fas-enriched Rafts in Selective Tumor Cell ApoptosisJournal of Experimental Medicine, 2004
- The Pathophysiology of Mitochondrial Cell DeathScience, 2004
- Regulatory Roles of JNK in Programmed Cell DeathThe Journal of Biochemistry, 2004
- Renal cell carcinomaCurrent Opinion in Oncology, 2001
- c-JUN Gene Induction and AP-1 Activity Is Regulated by a JNK-Dependent Pathway in Hypoxic HepG2 CellsExperimental Cell Research, 2001
- Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathwaysCell Research, 2000
- Hypoxia and Hypoxia/Reoxygenation Activate p65PAK, p38Mitogen-Activated Protein Kinase (MAPK), and Stress-Activated Protein Kinase (SAPK) in Cultured Rat Cardiac MyocytesBiochemical and Biophysical Research Communications, 1997